Helal et al. (2015) have revealed that the anticancer activity of Gef in combination with one of the chemotherapy regimens was related to a decrease in the expression of RAF-1 and inhibition of RAF/EGFR-activated signaling pathway in tongue cancer cells [13]. This evidence concerns the gene EGFR and tongue cancer.